Recent Patents in Circulating Cell-Free Tumor DNA as Biomarker in Cancer
Maria L. Antelo-Caamano,
Jose J. Illarramendi-Manas,
Angel G. Martin.
The prevalence of cancer in our days remains at high level all over the world. Implementing and improving tools
for better diagnostics and prognostics is a very active field of research aimed towards giving the patients the best possible
management of their disease. Since the discovery of the presence of cell-free circulating DNA (ccfDNA) in the blood of cancer
patients, it has been proposed as a tool for tumor diagnosis, follow-up of treatment and prognosis assessment. In fact, the
strong link with molecular alterations found in the tumor has demonstrated effective as a prognostic tool specially regarding
invasive types of cancers. Today, the circulating plasma tumor DNA (cptDNA), also known as liquid biopsy, promises an
outstanding clinical test in routine cancer patient management, which is currently used in numerous clinical trials as a secondary
parameter to follow outcome of the treatments being investigated. Besides describing patents covering specific markers,
several patents have been recently filed for methods of cptDNA analysis. In this review, we aim to provide with a succinct
summary of the current application of cptDNA as a tool for clinical management of the cancer patient.
Keywords: Circulating plasma tumor DNA, copy number variation, liquid biopsy, loss of heterozygosity, methylation, mutation,
Rights & PermissionsPrintExport